NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients

Victor Pallarès, Montserrat Hoyos, M. Carmen Chillón, Eva Barragán, M. Isabel Prieto Conde, Marta Llop, María Virtudes Céspedes, Josep F. Nomdedeu, Salut Brunet, Miguel Ángel Sanz, Marcos González-Díaz, Jorge Sierra, Isolda Casanova, Ramon Mangues

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

© Pallarès et al. Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Original languageEnglish
Pages (from-to)76003-76014
JournalOncotarget
Volume8
Issue number44
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Acute myeloid leukemia
  • Bcar1
  • Intermediate-risk
  • Nedd9
  • Prognostic factor

Fingerprint

Dive into the research topics of 'NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients'. Together they form a unique fingerprint.

Cite this